文献速递临床试验与 GCP基础与转化研究

Presepsin用于安全减少早产儿抗生素使用(PRESAFE):一项随机对照试验及同期观察性研究的研究方案

Presepsin to safely reduce antibiotics in preterm infants (PRESAFE): study protocol for a randomized controlled trial with a concurrent observational study.
PubMed 文献 · Trials · 2026-02-27

PRESAFE是一项多中心随机对照试验及同期观察性研究,纳入胎龄<32周的早产儿,按荷兰早产儿早发型败血症(EOS)指南将需要经验性抗生素者分为中危和高危,中危儿按1:1随机分为干预组(presepsin≥645 pg/ml才启动经验性抗生素)和对照组(按指南标准治疗),主要结局为培养证实的EOS发生率(非劣效)和不必要抗生素使用(优效),计划样本量900例;高危和低危儿进入同期观察性研究,评估presepsin诊断准确性。

要点

  • 胎龄<32周早产儿中,按荷兰EOS指南超过80%出生后即接受经验性抗生素,而EOS实际发生率仅1%-2%。
  • 中危儿随机分为干预组(presepsin≥645 pg/ml才启动经验性抗生素)与对照组(按指南标准治疗,等同于启动经验性抗生素)。
  • 随机对照试验计划样本量900例,共同主要结局为培养证实的EOS发生率(非劣效)和不必要抗生素使用(优效)。

核心结论

  • 该随机对照试验结果将为胎龄<32周早产儿疑似EOS安全有效减少抗生素使用提供证据;观察性研究将进一步揭示全部胎龄<32周早产儿中presepsin的诊断准确性。

研究设计与样本

  • PRESAFE试验为多中心随机对照试验,并包含同期观察性研究。
  • 在所有胎龄<32周早产儿中,从脐带血或首次常规采血时检测presepsin水平。
  • 按荷兰EOS指南符合经验性抗生素指征的早产儿,依据预设高危标准分为中危和高危;不符合经验性抗生素指征者归为低危。
  • 中危早产儿按1:1随机分为干预组和对照组;高危和低危早产儿不参与随机,进入同期观察性研究并按荷兰EOS指南治疗。
  • 随机对照试验所需样本量为900例。

主要发现

  • 按荷兰EOS指南,胎龄<32周早产儿中超过80%在出生后即接受经验性抗生素,而EOS实际发生率在1%至2%之间。
  • 随机对照试验的共同主要结局为培养证实的EOS发生率(非劣效)和不必要抗生素使用(优效)。
  • 观察性研究的主要结局为presepsin的诊断准确性。

关键数值与推荐

  • 干预组早产儿仅在presepsin水平达到预设的≥645 pg/ml时才启动经验性抗生素。
  • 对照组早产儿按荷兰EOS指南标准治疗,等同于启动经验性抗生素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate and rapid diagnosis of early-onset neonatal sepsis (EOS) in preterm infants remains problematic due to a lack of specific symptoms and diagnostic tools. Following the Dutch EOS guidelines, over 80% of infants born < 32 weeks of gestation are empirically started on antibiotics directly after birth, while the actual incidence of EOS varies between 1 and 2%. Unnecessary antibiotic exposure leads to severe short and long-term complications. The biomarker presepsin, also known as soluble CD14 subtype, may be used to reduce antibiotic prescription in preterm infants after birth. The objective of this study is to investigate whether adding a presepsin-guided decision to the guideline safely reduces antibiotic exposure directly after birth in preterm infants. Secondly, the diagnostic accuracy of presepsin for EOS will be evaluated. METHODS: The PRESAFE trial is a multicentre, randomized controlled trial (RCT), including a concurrent observational study. Presepsin levels are determined from umbilical cord blood or during the first regular blood draw in all infants born < 32 weeks gestation. Infants who qualify for empirical antibiotics according to the Dutch EOS guideline are categorized as moderate or high risk for EOS based on prespecified high-risk criteria. Infants not qualifying for empirical antibiotics are categorized as low risk. Preterm infants with a moderate risk for EOS are randomized 1:1 into an intervention arm and a comparator arm. In infants allocated to the intervention arm, empirical antibiotics will only be started above a prespecified presepsin level of ≥ 645 pg/ml. In the comparator arm, infants will be treated according to the standard of care following the Dutch EOS guideline, equivalent to starting empirical antibiotics. The co-primary outcomes of the RCT are the incidence of culture-proven EOS (non-inferiority) and unnecessary antibiotics administration (superiority). The required sample size for the RCT is 900 patients. Infants with a high- or low-risk of EOS are excluded from randomization but included in a concurrent observational study and treated according to the Dutch EOS guideline. The primary outcome of this part is the diagnostic accuracy of presepsin. DISCUSSION: The findings of the RCT will provide evidence for safe and effective reduction of administration of antibiotics for suspected EOS in infants born < 32 weeks of gestation. The observational study will provide more insight in the diagnostic accuracy of all infants born < 32 weeks of gestation. TRIAL REGISTRATION: ClinicalTrials.gov NCT06100614. First registered on October 25, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nusman CM, Taal HR, Vijlbrief DC, et al. Presepsin to safely reduce antibiotics in preterm infants (PRESAFE): study protocol for a randomized controlled trial with a concurrent observational study. Trials. 2026. PMID: 41749329. doi:10.1186/s13063-026-09515-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。